Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 3, 2025

NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025

View original at finance.yahoo.com
NTT Scientists Contribute Fifteen Research Papers to NeurIPS 2025 NTT Research, NTT, Inc. and NTT DATA showcase foundational theory, system-level advances and enterprise-grade innovations across five major themes at premier AI conference News Highlights: NTT Research, NTT, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI is becoming ubiquitous, but how these computational engines actually work remains—to a surprising degree—a mystery, which is why our scientists keep probing with fundamental questions

    80% confidence
  • Standard SAEs architectures embed implicit geometric assumptions that not only reveal concepts inside models but also shape what concepts can be discovered

    80% confidence
  • With the EU AI Act mandating watermarking, the topic has become increasingly urgent, and even state-of-the-art watermarking schemes can be reverse engineered, revealing significant risks for enterprises

    80% confidence
  • Researchers must keep pace with operational challenges in AI development

    80% confidence
  • Understanding training dynamics in in-context learning may enable engineering reliable ICL behavior

    80% confidence
  • The watermarking vulnerability findings expose a foundational vulnerability in today's AI trust and traceability mechanisms

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com